Health · Pharma & Biotech · 3 hrs ago
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Bristol Myers Squibb said its experimental drug admilparant slowed the loss of breathing capacity in a year-long Phase 3 trial involving people with idiopathic pulmonary fibrosis, a disease that causes scarring in the lungs.
The 60-milligram dose met the trial’s main goal, but the 120-milligram dose did not meet the standard for a statistically significant result.
That difference has raised questions about why the higher dose did not show a clearer benefit.
The company said the drug was generally well tolerated, with similar rates of treatment-related study dropouts across the groups.
Admilparant is the most advanced drug in a class designed to block a signal involved in lung scarring, and could offer another treatment option alongside existing medicines.
Earlier drugs in this class ran into problems in testing, including liver safety concerns.
Bristol Myers shares fell about 4% after initially rising, while analysts said more detailed trial results are needed to judge the drug’s prospects.
Bristol Myers Squibb said its experimental drug admilparant met the main objective in a Phase 3 trial for idiopathic pulmonary fibrosis at the 60 milligram dose.
The 120 milligram dose showed an effect on disease progression, but it did not meet the threshold for statistical significance.
The results raised questions among analysts about the drug’s dose response and prospects.
The company said the drug had a well-tolerated safety profile, with similar rates of treatment-related discontinuations across study groups.
- Who
- Bristol Myers Squibb reported the results for its experimental drug admilparant.
- What
- The 60 milligram dose met the trial’s main objective; the 120 milligram dose did not meet the statistical significance threshold.
- When
- Oct. 12, 2026.
- Where
- Not stated.
- Why
- The trial tested whether admilparant could slow the decline in breathing capacity in people with idiopathic pulmonary fibrosis.
Analysts questioning admilparant's prospects
Analysts more positive about the drug's prospects
Dose response
Analysts questioning admilparant's prospects
The high-dose result was confounding and the lack of dose response raised questions about the drug's profile.
Analysts more positive about the drug's prospects
The lower-dose success could open a major commercial opportunity despite lingering questions.
Bristol Myers changed safety monitoring protocols in Europe for admilparant’s trial.
Bristol Myers reported that the 60 milligram dose met the Phase 3 trial’s main objective, while the 120 milligram dose did not meet the statistical significance threshold.
- Drug
- Admilparant
- Disease
- Idiopathic pulmonary fibrosis
- Lower dose
- 60 milligrams met the trial’s main objective
- Higher dose
- 120 milligrams did not meet the statistical significance threshold
- Trial phase
- Phase 3
- Announcement
- Oct. 12, 2026
What people are saying
confounding and requires further explanation
These admilparant results represent an important advancement as there remains a need for therapies that are both effective and tolerable for patients living with IPF
We await detailed results to better understand the drug’s efficacy.
likely to open a blockbuster opportunity
Sources
Related news
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
EU approves evolocumab for adults at high cardiovascular risk
Brazil suspends Peptistrong supplement and orders all batches recalled
